Corticosteroid therapy for pneumonia

The Lancet

Volumn 386, Issue 9997, 2015, Pages 955-

  Zumla, Alimuddin ^a,b   Bates, Matthew ^a,b   Maeurer, Markus ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISONE; ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LENGTH OF STAY; LETTER; MESENCHYMAL STEM CELL TRANSPLANTATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; TREATMENT DURATION; TREATMENT OUTCOME; FEMALE; MALE;

ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; MALE; PNEUMONIA; PREDNISONE;

EID: 84941355878     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00065-3     Document Type: Letter

References (6)

1. A Zumla, ZA Memish, M Maeurer et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options Lancet Infect Dis 14 2014 1136 1149
2. CA Blum, N Nigro, M Briel et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 385 2015 1511 1518
3. MA Huson, MP Grobusch, T van der Poll The effect of HIV infection on the host response to bacterial sepsis Lancet Infect Dis 15 2015 95 108
4. A Zumla, J Chakaya, M Hoelscher et al. Towards host-directed therapies for tuberculosis Nat Rev Drugs Discov 14 2015 511 512
5. SH Kaufmann, C Lange, M Rao et al. Progress in tuberculosis vaccine development and host-directed therapies - a state of the art review Lancet Respir Med 2 2014 301 320
6. A Skrahin, RK Ahmed, G Ferrara et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial Lancet Respir Med 2 2014 108 122